A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials

Niayesh Najafi¹, Hussein Maatouk¹, Karapet Gary Vardanyan¹, Kevin Babakhan Vartanian¹, Devendra K. Agrawal¹*

¹Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, California 91766 USA.

^*Corresponding author: Devendra K. Agrawal, MSc, PhD (Biochem), PhD (Med Sci), MBA, MS (ITM), FAAAAI, FAHA, FAPS, FIACS Director and Professor, Department of Translational Research, Western University of Health Sciences, 309 E. Second Street, Pomona, California 91766, USA.ORCID:Devendra K. Agrawal: 0000-0001-5445-0013

Received: 21 August 2026; Accepted: 27 August 2026; Published: 29 August 2026

1. Introduction

GHK is a tripeptide composed of glycine, L-histidine, and L-lysine. It is endogenously present in human plasma, saliva, and urine, and is liberated from the alpha-2(I) chain of type I collagen and from the SPARC (secreted protein acidic and rich in cysteine) protein during proteolysis after tissue injury. The peptide exhibits a high affinity for copper (II), forming the bioactive complex GHK-Cu (also commercially designated copper tripeptide-1). Plasma concentrations of GHK decline with age, falling from approximately 200 ng/mL at age 20 to roughly 80 ng/mL by age 60, a reduction that parallels the age-associated decline in tissue regenerative capacity.

Across several decades of investigation, GHK-Cu has been shown to influence multiple processes relevant to tissue repair, including collagen and glycosaminoglycan synthesis, fibroblast proliferation, keratinocyte stemness preservation, wound contraction, angiogenesis. In addition, GHK-Cu appears to modulate oxidative stress and inflammatory signaling, including upregulating of superoxide dismutase and catalase, suppression of NF-κB activity, and broad transcriptional remodeling. Connectivity Map analyses suggests that GHK-Cu exposure alters gene expression in over 30 percent of measured human genes by at least 50 percent, with most of these changes associated with a shift from diseased toward more physiologic expression patterns [1].

Despite this growing body of mechanistic evidence, the translational landscape remains limited. Much of the clinical literature that has shaped product development is derived from a small number of facial cream studies conducted in the early 2000s, which have not been replicated in larger or more rigorous modern trials. At the same time, the question of drug delivery remains a central challenge, particularly given the difficulty of transporting a hydrophilic, charged tripeptide across the stratum corneum at therapeutically meaningful concentrations. While this problem has been explored extensively in laboratory and preclinical settings, clinical translation remains minimal.  Microneedle-assisted delivery has emerged as a potential strategy to overcome this barrier. In one study using in vitro and porcine model, microneedle pretreatment increased GHK-Cu permeation through human skin from negligible amounts to 134 ± 12 nanomoles of peptide and 705 ± 84 nanomoles of copper over nine hours [2]. However, these findings have not yet been validated in large-scale human studies, and no large randomized human trial of GHK-Cu paired with microneedle delivery has been published.

This gap is clinically relevant. GHK-Cu has undergone regulatory scrutiny, including FDA review with Category 2 restriction on injectable compounding as of 2023 and continued evaluation under PCAC through 2026. At the same time, the cosmetic and aesthetic medicine markets are increasingly populated with products that combine microneedle devices, dermarollers, and copper peptide serums without rigorous clinical Validation. Addressing this disconnect requires a saturated synthesis of the existing evidence, identification of the strongest animal and ex vivo signals, and a clear framework for future clinical trial design.

2. Physiology and Collagen Repair: Mechanistic Foundation of GHK-Cu Activity

2.1 The Three-Phase Wound Healing Model and Site of Action of GHK-Cu

Cutaneous wound repair proceeds through three overlapping phases: hemostasis and inflammation, proliferation and migration, and maturation and remodeling [67]. The first phase begins within minutes of injury and is dominated by platelet aggregation, vascular permeability changes, cytokine release, and neutrophil and macrophage recruitment. The second phase, beginning day three and extending through approximately day fourteen, is characterized by fibroblast migration into the wound bed, deposition of extracellular matrix, keratinocyte migration from the wound edges to cover the defect, and angiogenesis driven by vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). The final phase, maturation and remodeling, starts from approximately day twenty-one through one to two years post-injury, during which collagen III is replaced by collagen I, fiber bundles are reorganized, and tensile strength is recovered. A failure or delay in any of these phases produces the clinical phenotype of chronic, non-healing, or hypertrophic scarring [67].

GHK-Cu acts at every phase. During hemostasis and inflammation, it dampens NF-κB activation, suppresses TNF-α and IL-1β, and reduces neutrophil-driven oxidative damage. During proliferation, fibroblast collagen and glycosaminoglycan synthesis is stimulated which supports keratinocyte stemness preservation through p63 and integrin α6/β1 upregulation.  It also drives angiogenesis through both VEGF/bFGF induction and direct chemoattraction of capillary endothelial cells. During maturation and remodeling, it supports balanced TIMP/MMP regulation that prevents both inadequate matrix deposition (as seen in chronic ulcers) and excessive deposition (as seen in hypertrophic scarring) [1, 12, 39, 67].

2.2 GHK as an Endogenous Matricryptin

A critical and often underappreciated feature of GHK-Cu biology is that the molecule is not merely an exogenous peptide that humans happen to respond to,it is an endogenous matricryptin. Matricryptins (a term introduced by Davis et al. and now standard in extracellular matrix biology) are biologically active fragments released from larger ECM proteins through proteolytic cleavage during tissue injury [68]. The GHK sequence is cleaved from at least two parent molecules: the alpha-2 chain of collagen I and the matricellular protein SPARC (secreted protein acidic and rich in cysteine) [69, 70]. Lane et al. demonstrated that proteolytic degradation of SPARC during vascular remodeling releases a (K)GHK containing peptide that binds Cu²⁺ with high affinity and stimulates angiogenesis in chick chorioallantoic membrane assays and bovine aortic endothelial cell tube-formation assays [69]. The collagen Iα2-derived GHK fragment is similarly chemotactic for monocytes, macrophages, and mast cells, and possesses proangiogenic activity in cardiac wound healing contexts [70].

This distinction matters mechanistically because it places GHK-Cu in a different category from synthetic peptides designed to mimic biological signals. The peptide is a signaling molecule the body itself uses, generated at the site of tissue injury. Exogenous topical application is best understood as supplementing an endogenous repair signal whose plasma concentration declines with age rather than the introduction of a foreign molecule. This change is from approximately 200 ng/mL at age twenty to approximately 80 ng/mL by age sixty [1, 60]. The therapeutic logic of GHK-Cu supplementation is therefore analogous to hormone replacement: restoration of a signaling molecule that is naturally produced but quantitatively diminished with age.

2.3 Copper as the Essential Cofactor for Collagen and Elastin Cross-Linking

The collagen promoting activity of GHK-Cu cannot be separated from copper’s role as an essential cofactor for the lysyl oxidase (LOX) family of enzymes. Lysyl oxidase is a copper dependent amine oxidase that catalyzes the oxidative deamination of specific lysine and hydroxylysine residues in collagen and elastin, generating reactive aldehyde groups that spontaneously condense with adjacent residues to form the covalent cross-links that confer tensile strength and elastic recoil to connective tissue [71, 72]. Without adequate copper at the active site, newly synthesized collagen molecules remain unlinked, mechanically weak, and susceptible to proteolytic degradation. The LOX family includes five members, LOX, LOXL1, LOXL2, LOXL3, and LOXL4, all of which share a conserved C-terminal catalytic domain containing the lysine tyrosylquinone (LTQ) cofactor and the copper-binding site [72]. Copper is essential for the post-translational formation of the LTQ cofactor through copper-catalyzed oxidation of an active-site tyrosine residue [71].

Lysyl hydroxylase (procollagen-lysine 5-dioxygenase, PLOD), a separate enzyme that hydroxylates lysine residues in nascent collagen chains prior to LOX-mediated cross-linking, is iron-dependent rather than copper-dependent but its substrate availability and the downstream stability of its product depend critically on adequate copper-mediated cross-linking. The integrated activity of lysyl hydroxylase followed by lysyl oxidase determines whether collagen synthesized in fibroblasts will be assembled into functional load-bearing fibers or will remain as poorly cross-linked, easily degraded substrate.

GHK-Cu delivers copper directly to fibroblasts and keratinocytes in a chelated, bioavailable form. The peptide’s binding constant for Cu²⁺ is approximately log K = 16.44 at physiological pH, high enough that the GHK-Cu complex remains intact during transport but exchangeable enough that copper can be released to high-affinity intracellular acceptors. This delivery mechanism is mechanistically distinct from inorganic copper salts: the peptide protects copper from non-specific binding to plasma albumin and ceruloplasmin and may facilitate delivery to cells expressing the relevant uptake machinery.

2.4 Type I and Type III Collagen, Decorin, and Glycosaminoglycan Synthesis

GHK-Cu stimulates synthesis of multiple ECM components in a coordinated rather than nonspecific manner. In the foundational fibroblast culture work by Maquart et al. (1988), and in subsequent in vivo rat experimental wound studies (1993), GHK-Cu at low nanomolar concentrations was shown to stimulate both collagen synthesis and glycosaminoglycan production [62, 63]. Subsequent work further characterized these effects: GHK-Cu has been shown to upregulate type I collagen (the structural collagen that confers tensile strength to mature dermis), type III collagen (the more flexible collagen that predominates in early wound repair), and the small leucine-rich proteoglycan decorin [1, 12, 39].

Decorin is a key regulator of collagen organization. It binds collagen fibrils at specific positions and regulates their lateral assembly into ordered fiber bundles. In normal dermis, decorin-organized collagen fibers run in regular, basket-weave patterns that confer the characteristic mechanical and optical properties of skin. In scar tissue, by contrast, collagen fibers run in parallel, randomly oriented bundles with diminished decorin content, a structural difference that is associated with the visual prominence of scars and reduced tensile strength relative to normal skin [1, 39]. GHK-Cu’s stimulation of decorin alongside collagen therefore likely contributes to its anti-scarring effects: the peptide does not simply increase collagen output, it may also influence its structural organization.

The glycosaminoglycans stimulated by GHK-Cu, including dermatan sulfate, chondroitin sulfate, and heparan sulfate, are involved in maintaining hydration, viscoelastic properties, and growth factor binding within the regenerating matrix. Heparan sulfate proteoglycans bind and present growth factors such as FGF and VEGF to their receptors, thereby supporting angiogenic and mitogenic signaling pathways that may complement the effects of GHK-Cu

2.5 The TGF-β3 Pathway and Reduced Fibrosis

A distinct mechanistic feature of GHK-Cu’s activity is its modulation of the transforming growth factor beta family. The three TGF-β isoforms have divergent effects on wound repair: TGF-β1 and TGF-β2 are associated with fibrotic, scar-forming healing responses, while TGF-β3 has been associated with scarless healing characterized by more orderly collagen deposition and reduced fibrosis [39]. Resnik et al., in their 2025 comprehensive tripeptide review, describe TGF-β3 pathway upregulation as a potential mechanism through which GHK-Cu and related tripeptides may contribute to reduced-scar wound healing [39]. The same review also notes that GHK-Cu has been associated with balanced collagen synthesis, accelerating epithelialization, and reduced fibrosis in in vitro and preclinical models.

This TGF-β3 mechanism may help explain observations from animal models in which GHK-Cu-treated wounds exhibit thinner and more cosmetically acceptable scars compared to controls and provides a potential biological rationale for the surgical wound healing applications discussed in Section 6.7.

2.6 Antioxidant and Anti-Inflammatory Mechanisms

GHK-Cu modifies the oxidative and inflammatory environment of the healing wound through multiple complementary mechanisms.

First, it directly neutralizes reactive carbonyl species. Beretta et al. demonstrated that GHK reacts with 4-hydroxy-2-nonenal and with acrolein, two highly toxic products of lipid peroxidation that propagate oxidative damage and promote nonspecific protein crosslinking, to form non-toxic adducts [73, 74]. This quenching activity is independent of copper binding and likely reflects the chemical reactivity of the histidine and lysine side chains.

Second, GHK-Cu inhibits ferritin-dependent lipid peroxidation. Miller et al., in foundational work cited within the post-2005 review literature, demonstrated that GHK-Cu reduces iron release from ferritin by approximately 87 percent [75]. Iron (II) released from ferritin in damaged tissue is an important contributor of the Fenton reaction, generating hydroxyl radicals that propagate lipid peroxidation chains. GHK-Cu has been proposed to interact with ferritin channels involved in iron release, thereby limiting iron(II) efflux and potentially reducing oxidative propagation. This mechanism is particularly relevant in wounds with hemorrhage and tissue injury, where free iron from extravasated red cells and damaged ferritin stores may contribute to sustained oxidative stress.

Third, GHK-Cu modifies the gene expression of antioxidant defense systems. The peptide has been associated with upregulation of copper-zinc superoxide dismutase (SOD1), catalase, and elements of the glutathione synthesis pathway, while downregulating components of the NF-κB inflammatory cascade. Park et al. (2016) and Zhang et al. (2022) confirmed in vivo that GHK-Cu administration to mice with lipopolysaccharide-induced acute lung injury and cigarette-smoke-induced pulmonary emphysema, respectively, suppressed NF-κB activation, reduced TNF-α and IL-6 levels, and protected tissue architecture [13, 14]. The same anti-inflammatory mechanism may also contribute to cutaneous wound healing responses.

2.7 Cellular Stemness, p63, and Integrin α6/β1

A more recently recognized aspect of GHK-Cu’s activity is its preservation of basal keratinocyte and dermal fibroblast stemness. Kang et al. (2009) demonstrated that GHK-Cu treatment increased expression of integrin α6 and integrin β1, the laminin receptor heterodimer that anchors basal keratinocytes to the basement membrane and is associated with the keratinocyte stem cell phenotype [3]. The same study showed increased nuclear positivity for p63, a transcription factor required for maintenance of keratinocyte proliferative potential and commonly used as a marker of basal-layer stem cells [3]. Choi et al. (2012) extended these findings to copper-free GHK, showing that even without the copper chelate, the peptide alone may exert stem-cell-supportive effects in skin [4].

The clinical implication is significant. Most regenerative interventions stimulate cellular proliferation and matrix deposition but do not specifically protect or expand the stem cell pool that maintains long-term tissue renewal. GHK-Cu’s potential stem cell-supporting activity may explain the durable improvements seen in skin quality after extended GHK-Cu exposure, as opposed to the transient improvements seen with growth factors that primarily drive committed-cell proliferation.

2.8 Connectivity Map: The Genome-Scale Picture

The mechanistic actions described above represent individual molecular pathways modulated by GHK-Cu. At the systems level, the most striking finding is the breadth of the gene-expression changes the peptide produces. Connectivity Map analyses of GHK-Cu-exposed cell lines indicate that the peptide alters expression of more than 4,000 genes, approximately one third of all measured genes, by at least fifty percent in either direction [1]. The pattern of changes is nonrandom: when compared against gene-expression signatures of disease states, GHK-Cu’s signature has been associated with shifts toward more physiologic cellular phenotypes. Notably, GHK-Cu reverses the gene-expression signature of emphysema-related lung destruction in human bronchial epithelial cells (Campbell et al., 2012) and has also been associated with partial reversal of metastasis-prone gene signatures in colorectal cancer cell lines [1, 60].

The “genome-resetting” framing that has appeared in some review articles likely overstates the directness of these effects, as GHK-Cu is not editing DNA. However, the underlying observation remains notable: the peptide modifies transcription across a broad set of genes in a pattern consistent with a shift toward more physiologic baseline cellular activity. For cutaneous wound healing and aging skin, this means GHK-Cu’s collagen-stimulating, anti-inflammatory, and antioxidant activities are not isolated effects but components of an integrated transcriptional program.

3. Objectives of the Systematic Review

The primary objective of this review is to synthesize the GHK-Cu literature published between 2005 and 2026 and to identify, with explicit reference to study model and study quality, the current evidence supporting advancement toward human clinical trials of topical GHK-Cu delivered via microneedle or microneedle-adjacent platforms. The specific aims include: (i) To map the breadth and depth of preclinical (in vitro and animal) GHK-Cu evidence within the twenty-year window, (ii) To catalog all human clinical evidence for GHK-Cu and characterize its limitations in study size, design, and delivery mechanism, (iii) To compare GHK-Cu against the most relevant therapeutic comparators (retinoids, vitamin C, palmitoyl pentapeptide, EGF, PRP, microneedling alone, minoxidil), with comparator selection matched on study model (in vitro to in vitro, rodent to rodent, human to human), and (iv) To identify the specific clinical questions that remain unresolved and propose the trial-design framework needed to answer them.

4. Methods (PRISMA-Aligned)

4.1 Protocol and Registration

This review was conducted using a protocol developed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) framework. The protocol was not pre-registered with PROSPERO; accordingly, this review is best characterized as a structured narrative review with PRISMA-aligned methodology rather than a formally registered systematic review.

4.2 Eligibility Criteria

Inclusion criteria: - Peer-reviewed primary research articles, systematic reviews, or narrative reviews - Published between 1 January 2005 and 1 May 2026 - English language - GHK-Cu, GHK, glycyl-l-histidyl-l-lysine-Cu, or copper tripeptide-1 as a primary or secondary intervention or analytical focus - Any study model (in vitro, ex vivo, in vivo animal, ex vivo human, in vivo human) - Reports either a primary outcome related to tissue repair, skin biology, hair biology, anti-inflammatory effect, antioxidant effect, gene expression, or pharmaceutical delivery, or comparative analysis of GHK-Cu against an alternative therapy

Exclusion criteria: - Conference abstracts without full-text publication - Patent filings, regulatory submissions, marketing literature - Commentaries and editorials without original data - Articles published before 2005 (foundational publications by Pickart 1973, Maquart 1988/1993, Wegrowski 1992, and Mulder 1994 are referenced for historical context only via citations within review articles that fall inside the inclusion window)

4.3 Information Sources

Three databases were searched: PubMed/MEDLINE (via the National Library of Medicine), Elsevier ScienceDirect (Elsevier B.V.), and the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Library. The Cochrane database was selected as the third source because it provides controlled-trial coverage that complements the broader scope of PubMed and ScienceDirect. The final search was performed on 28 April 2026.

4.4 Search Strategy and Keywords

The following Boolean strings were used (adapted to each database’s syntax):

Primary string: (“GHK-Cu” OR “GHK Cu” OR “glycyl-histidyl-lysine-copper” OR “glycyl-L-histidyl-L-lysine-Cu” OR “copper tripeptide-1” OR “copper tripeptide”)

Topic strings combined with the primary string using AND: - (wound OR ulcer OR healing OR “tissue repair” OR regeneration) - (skin OR dermal OR fibroblast OR keratinocyte OR collagen OR elastin OR aging OR “anti-aging” OR photodamage OR photoaging OR wrinkle) - (hair OR follicle OR alopecia OR “dermal papilla”) - (inflammation OR antioxidant OR “oxidative stress” OR “NF-kB” OR cytokine) - (microneedle OR microneedling OR transdermal OR liposome OR microemulsion OR “ionic liquid” OR hydrogel OR scaffold OR delivery) - (gene OR genome OR “gene expression” OR transcriptome)

Filters applied: publication date 2005/01/01 - 2026/05/01; English language; humans, animals, or in vitro models permitted.

4.5 Study Selection

Two screening rounds were performed: (i) title and abstract screening against eligibility criteria; (ii) full-text screening of remaining records. Reference lists of included reviews were hand-searched to capture any records missed by the database queries (snowball method). Duplicates across databases were removed by DOI matching and, where DOIs were absent, by title-author-year matching.

4.6 Data Extraction

For each included record, the following fields were extracted: author and year, study type (in vitro, ex vivo, in vivo rodent, in vivo non-rodent, human cohort, human RCT, narrative review, systematic review), GHK-Cu form and concentration tested, comparator (where applicable), primary outcome, key result, and DOI.

4.7 Risk of Bias Assessment

For human RCTs, risk of bias was evaluated qualitatively using the domains defined in the Cochrane Risk of Bias 2 (RoB 2) tool (randomization, deviation from intended interventions, missing outcome data, outcome measurement of, and selection of reported result). For animal studies, the SYRCLE risk-of-bias framework principles were applied informally given the heterogeneity of study reporting. A formal meta-analysis was not conducted because of the heterogeneity in study models, GHK-Cu formulations, dosing strategies, and outcome measures.

5. PRISMA Flow Diagram (Tabular)

Because this review was not registered as a formal systematic review and is delivered as a written document, the PRISMA flow is presented in tabular form below. Records are reported following PRISMA 2020 guidance.

Table: PRISMA flow

6. Results: Summary of Included Studies

6.1 Master Table of Included Studies

The 64 included records are tabulated below, grouped by study model and ordered chronologically within each group (Table 1; Figure 1). Comparator information, where present, is included so that the reader can map any individual study to the appropriate row of the comparator analysis (Section 7) (Figure 1).

Table 1: Master Table of Included Studies. Records 4, 9, 10, 12, 13, 18, 19, 20, 21, 31, 41, 42, 44, 45, 46, 47, 49, 50, 60 are reviews and provide narrative context; the remaining records are primary research. Foundational papers from 1988 to 1994 (Maquart, Wegrowski, Mulder) fall outside the 20-year window and are not enumerated as primary inclusions. They are referenced in this review only via the post-2005 review articles in which they appear (notably records 4, 12, and 19), in keeping with the eligibility rules stated in Section 4.2.

Figure 1: PRISMA 2020 flow diagram and stratification of included GHK-Cu studies by model type. Panel A depicts the PRISMA 2020-aligned flow of records through the four review stages. A total of 1,247 records were identified through database searching and citation chasing (PubMed n = 612, ScienceDirect n = 487, Cochrane CENTRAL n = 89, hand search n = 59), of which 891 remained after duplicate removal. Title and abstract screening excluded 731 records, leaving 160 reports sought for retrieval; 14 could not be retrieved due to lack of full-text access. The remaining 146 reports underwent full-text eligibility assessment, of which 82 were excluded with documented reasons (pre-2005 foundational only n = 19; not focused on GHK or GHK-Cu n = 28; conference abstract only n = 11; editorial or commentary n = 9; non-English n = 4; marketing or regulatory document n = 11). Sixty-four studies met all inclusion criteria and were carried forward to qualitative synthesis. No quantitative meta-analysis was performed; substantial heterogeneity in study population, GHK-Cu formulation, dose, delivery vehicle, comparator, outcome instrument, and follow-up duration precluded statistical pooling. Panel B stratifies the 64 included records by primary study model. Reviews, including both narrative and systematic reviews, constitute the largest single category at 24 records (37.5 %), reflecting the substantial secondary literature available on the molecule. Direct primary evidence, when partitioned by experimental system, is dominated by preclinical work: in vitro cell-based studies (n = 10, 15.6 %), in vivo rodent models (n = 9, 14.1 %), ex vivo human or porcine skin (n = 4, 6.2 %), pharmaceutical and delivery-system bench studies (n = 4, 6.2 %), and in vivo non-rodent animal studies (n = 2, 3.1 %). Human clinical studies number only 11 (17.2 %), and as the footer notes, 8 of these 11 do not test GHK-Cu as the experimental intervention but instead use it as an active comparator against vitamin C, EGF, tretinoin, Pal-KTTKS, or microneedling alone — leaving only one human pilot trial (Badenhorst 2016), one split-face study (Khanna 2025), and one case series (Kuceki 2025) that directly evaluate GHK-Cu in humans within the 20-year search window. The color encoding in Panel B (green = human clinical evidence, blue ramp = preclinical evidence, gray = reviews and narrative synthesis) highlights the imbalance within the current evidence base and underscores the translational gap identified throughout the review. Abbreviations: EGF, epidermal growth factor; GHK, glycyl-L-histidyl-L-lysine tripeptide; GHK-Cu, glycyl-L-histidyl-L-lysine-copper (II) complex; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

6.2 Mechanism and Cellular Pharmacology (in vitro)

The literature of the in vitro studies published since 2005 is mechanistically consistent with the foundational pre-2005 work but adds substantial granularity, particularly in the areas of epidermal stem cell biology and gene expression.

Kang et al. showed that GHK-Cu at 0.1-10 µM raises proliferating cell nuclear antigen (PCNA) and p63 expression in basal keratinocytes of skin equivalents, alongside elevated integrin α6 and β1 expression, a biomarker pattern consistent with preserved stemness and proliferative potential [3]. Choi et al. followed this with the demonstration that copper-free GHK reproduces several of these effects, suggesting that the peptide itself, and not solely the chelated copper, contributes to keratinocyte signaling [4].

Pollard et al. showed that GHK-Cu accelerates the proliferation of both normal and irradiated dermal fibroblasts and elevates bFGF and VEGF early in the response, providing a mechanistic basis for the recovery of fibroblast activity after radiation therapy [5]. Badenhorst et al. quantified the dose-dependence: at 0.01, 1, and 100 nM, GHK-Cu increased collagen and elastin production, with all concentrations elevating TIMP1, while only the lower concentrations increased MMP1 and MMP2 expression [6]. The dose-response is biphasic; higher concentrations attenuate or invert the regenerative effect, a pattern consistent with the original Maquart 1988 observations cited in subsequent reviews.

Jiang et al. introduced an important formulation insight: when GHK-Cu is co-applied with low-molecular-weight hyaluronic acid at a 1:9 ratio, collagen IV production rises 25.4-fold in dermal fibroblasts and 2.03-fold in ex vivo skin, suggesting a synergistic interaction that may have implications for delivery formulations , since collagen IV is the principal scaffold of the dermal-epidermal junction [7]. The Pickart-Margolina 2018 review aggregates the gene expression evidence: Connectivity map analysis indicates GHK-Cu affects expression of thousands of genes by at least 50%, including 47 DNA repair genes (mostly upregulated) and a wide panel of antioxidant and proteasome-system genes [1].

The in vitro story is broadly consistent: across fibroblasts, keratinocytes, dermal papilla cells, mesenchymal stem cells, and endothelial cells, GHK-Cu appears to function as a low-nanomolar trophic and remodeling signal with a defined biphasic dose-response. The major limitation of this body of evidence is not in its consistency but in its translation: cellular signal effects does not automatically equal clinical outcomes.

6.3 In Vivo Animal Evidence (Rodent and Non-Rodent)

The animal evidence published in the past two decades is concentrated in three areas: cutaneous wound healing, hair growth, and inflammation models in lung and gastrointestinal tissue.

Cutaneous wound healing. Arul et al. studied biotinylated GHK incorporated into a collagen matrix (peptide-incorporated collagen, PIC) in streptozotocin-induced diabetic rats. PIC accelerated wound contraction, raised glutathione and ascorbic acid, and increased granulation collagen up to nine-fold compared with untreated controls representing a substantial effect in a poorly healing model [8]. Wang et al. encapsulated GHK-Cu in liposomes and tested it in a mouse scald model: liposome-delivered GHK-Cu raised HUVEC proliferation by 33.1%, elevated VEGF and FGF-2 expression, and yielded superior CD31 and Ki67 staining in burned skin compared with free GHK-Cu [9]. Islam et al. demonstrated that GHK-Cu silver nanoparticles closed S. aureus-infected wounds within 24 hours at low minimum inhibitory concentrations, combining the antibacterial activity of silver with the regenerative signaling properties of GHK-Cu [10].

Hair growth. Two recent studies are particularly relevant. Tian et al. developed nanoliposomes co-loaded with GHK-Cu, acetyl tetrapeptide-3, and myristoyl pentapeptide-4 (“CAM-NLPs”) and showed that they upregulated VEGF and β-catenin while downregulating TGF-β1 in a C57BL/6 mouse model of androgenetic alopecia [11]. Liu et al. developed an ionic-liquid microemulsion (“CaT-ME”) for GHK-Cu and showed in mice that anagen entry occurred at six days compared with eight days for free GHK-Cu and nine days for minoxidil, without measurable effects on testosterone or estradiol [12]. The latter finding is one of the few head-to-head animal comparisons of GHK-Cu against the standard-of-care hair growth therapy.

Inflammation. Park et al. tested intra-tracheal GHK-Cu in a lipopolysaccharide-induced acute lung injury mouse model: GHK-Cu suppressed Ser536 phosphorylation of NF-κB p65, reduced TNF-α and IL-6, raised SOD activity, and reduced histological lung injury scores [13]. Zhang et al. extended this to a chronic cigarette-smoke emphysema model, showing that intraperitoneal GHK-Cu (medium and high dose, 2 and 20 µg/g/day) suppressed NF-κB activity and elevated Nrf2-driven antioxidant defense [14]. Mao et al. demonstrated in 2025 that rectal GHK-Cu in DSS-induced ulcerative colitis improved tight-junction protein expression (ZO-1, occludin) and suppressed STAT3 phosphorylation through SIRT1/STAT3 modulation [15].

Tendon and joint healing. Ho et al. used a rat anterior cruciate ligament reconstruction model and showed that intra-articular GHK-Cu at 0.3 mg/mL reduced knee laxity and improved graft stiffness at six weeks, but the effect did not persist to twelve weeks once treatment was discontinued, suggesting that the biological effects of GHK-Cu may require sustained exposure rather than producing durable tissue remodeling after a limited dosing period [16].

Across the animal literature, the recurring pattern is similar to that observed in vitro: consistent positive effects, with the strongest effects observed when GHK-Cu is delivered in a sustained-release vehicle such as collagen matrix, liposome, microemulsion, or scaffold rather than as free peptide.

Figure 2: Mechanistic pathways by which GHK-Cu supports cutaneous repair, extracellular matrix remodeling, and anti-inflammatory wound healing.

The Hub-and-spoke schematic shown in Figure 2 synthesizing the five mechanistic axes through which the glycyl-L-histidyl-L-lysine-copper (II) complex exerts its dermal effects, as supported by the in vitro, ex vivo, and in vivo evidence reviewed in Section 2. (1) ECM production (green); GHK-Cu upregulates fibroblast synthesis of type I and type III collagens and increases dermal glycosaminoglycan content, reconstituting the structural and water-binding components of the extracellular matrix. (2) Matrix organization (purple); GHK-Cu induces decorin expression and promotes the formation of well-organized, regularly spaced collagen fibrils characteristic of unwounded dermis rather than the disorganized, parallel-bundled collagen typical of scar tissue. (3) Copper-dependent crosslinking (blue); the bound Cu²⁺ ion serves as the obligate catalytic cofactor for lysyl oxidase (LOX), the enzyme that initiates covalent crosslinking of collagen and elastin fibers and thereby contributes to the tensile strength of the regenerated dermal matrix. (4) Anti-inflammatory and antioxidant activity (red); GHK-Cu suppresses NF-κB-driven transcription of the pro-inflammatory cytokines TNF-α and IL-6, upregulates the cellular antioxidant enzymes superoxide dismutase and catalase, and attenuates ferritin-mediated lipid peroxidation, collectively reducing the oxidative and inflammatory milieu that drives chronic, non-healing wounds. (5) Regenerative cell signaling (amber); GHK-Cu enhances expression of the basal-keratinocyte transcription factor p63 and of integrins α₆ and β₁, preserving the proliferative potential and stem-like phenotype of basal keratinocytes and fibroblasts involved in  re-epithelialization and dermal repopulation. The convergence of these five axes, substrate provision, structural organization, covalent stabilization, inflammatory and oxidative restraint, and regenerative cell competence, constitutes the biological rationale for clinical evaluation of GHK-Cu in photoaging, atrophic scarring, alopecia, and chronic wound indications. Abbreviations: ECM, extracellular matrix; GAG, glycosaminoglycan; LOX, lysyl oxidase; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; TNF-α, tumor necrosis factor alpha; IL-6, interleukin-6; SOD, superoxide dismutase; p63, tumor protein p63.

6.4 Human Clinical Evidence

This is the section where the evidence base is least developed.

The 2002 Leyden trials, frequently cited but published only as American Academy of Dermatology meeting abstracts, reported that twelve weeks of facial cream containing GHK-Cu in 71 women with mild-to-advanced photodamage improved skin density and thickness, reduced laxity and fine lines, and improved clarity. A second 2002 abstract reported that an eye cream containing GHK-Cu in 41 women outperformed placebo and vitamin K cream on periorbital wrinkling and skin density. These trials form the bases of the clinical claims for GHK-Cu in cosmetic use, but neither was published as a full peer-reviewed paper, and neither falls within the 2005-2026 inclusion window. They are referenced through the Pickart-Margolina 2018 review [1] for context only.

Within the inclusion window, the Badenhorst 2016 study includes a small volunteer wrinkle assessment that demonstrated 55.8% relative reduction in wrinkle volume and 32.8% reduction in wrinkle depth at eight weeks compared with control, although the sample was small and the study was published in a low-impact journal [6]. The Jiang 2023 ex vivo human skin work supports the dermal-epidermal junction findings but is not a clinical trial in the regulatory sense [7].

The single most relevant recent human study is the 2025 Khanna split-face investigation comparing dermaroller monotherapy against dermaroller plus 0.5-1% GHK-Cu serum in patients with acne scars. The combination group showed an early improvement in Goodman & Baron scores, but by week 16 there was no significant difference between groups, and the authors flagged a hyperpigmentation risk in the GHK-Cu arm [17]. A 2019 case series by Bhargava and Trivedi reached a similar conclusion regarding GHK-Cu plus dermaroller for acne scars: a 50.3% Goodman & Baron score reduction in the combined group versus 26.3% in the dermaroller-only group, with the strongest effect in boxcar scars.

The 2025 Kuceki case series is the closest published example of a microneedle-adjacent human delivery approach involving copper peptides: minoxidil, dutasteride, and copper peptides delivered together via tattooing device across five monthly sessions in androgenetic alopecia, with 26.5% area regrowth on AI-blinded assessment [18]. The series is small, uncontrolled, and combines GHK-Cu with two pharmacologically active comparators, so it cannot be used to isolate the GHK-Cu effect.

In summary: the human evidence base consists of a handful of small trials and series, mostly at the cosmetic-cream level. There is no published full-text randomized controlled trial of topical GHK-Cu delivered specifically via dissolvable, hollow, or solid microneedle arrays.

6.5 Delivery Systems: Microneedles, Liposomes, Microemulsions, Hydrogels

The delivery literature is quantitatively the most developed area informing the future direction of GHK-Cu clinical research.

Hostynek et al. established the baseline: aqueous GHK-Cu at 0.68% has a permeability coefficient through human cadaver epidermis of approximately 3 × 10⁻⁷ cm/h, with retention of 0.6-2.8% across stratum corneum, total epidermis, and split-thickness skin [19]. The peptide is hydrophilic and charged; passive diffusion across intact stratum corneum is poor.

The Li 2015 study is the principal early microneedle paper for GHK-Cu. Polymeric microneedle pretreatment of human skin at 700 µm needle height yielded 134 ± 12 nanomoles of peptide and 705 ± 84 nanomoles of copper across the skin in nine hours, compared with essentially nothing for untreated skin [2]. Importantly, the study also assessed safety: no clinically significant skin irritation was observed in cellular and porcine models. This in vitro and animal benchmark has stood for a decade without a published human trial that translates the finding.

Liposomes (Wang 2017 [9], Dymek 2023 [20]), ionic liquids (Liu 2022 ACS Sustainable [21]), and ionic-liquid microemulsions (Liu 2023 Bioactive Materials [12]) all show ex vivo or in vivo improvements in GHK-Cu permeation and stability, with the IL-microemulsion approximately tripling permeation versus PBS-vehicle and the liposome system tripling permeation versus free peptide. Sharma et al. developed a stimuli-responsive polymer gel for sustained GHK-Cu release, suitable for chronic wound dressings [22]. Klontzas et al. developed an oxidized alginate-GHK hydrogel scaffold for bone tissue engineering and showed enhanced osteogenic differentiation of cord-blood mesenchymal stem cells [23].

Across delivery systems, the consensus is consistent: GHK-Cu requires a delivery vehicle to be clinically meaningful, and microneedle-based delivery is the only clinically translatable physical method that has demonstrated reliable transport of the peptide across full human skin in published data.

Figure 3: The Central Translational Gap: Free topical versus microneedle-assisted GHK-Cu delivery across human skin. There is strong skin permeation rationale but there are no adequately powered human microneedle GHK-Cu trials.

The information in Figure 3 illustrates the central translational barrier in GHK-Cu therapy: limited penetration of free topical GHK-Cu across the intact stratum corneum versus enhanced dermal delivery after microneedle pretreatment. In untreated skin, the hydrophilic, charged GHK-Cu peptide demonstrates negligible permeation, limiting access to viable epidermal and dermal targets. Microneedle pretreatment creates transient aqueous microchannels through the stratum corneum, increasing passage of both GHK-Cu peptide and copper into the epidermis and dermis, where fibroblasts, keratinocytes, and extracellular matrix compartments can be reached. In the cited ex vivo human skin permeation model, microneedle pretreatment enabled 134 ± 12 nmol peptide and 705 ± 84 nmol copper to permeate over 9 hours, compared with negligible permeation without microneedles. Despite this promising delivery rationale, adequately powered human randomized trials evaluating microneedle or microneedle-adjacent GHK-Cu delivery remain unavailable.

6.6 Tissue-Engineering and Scaffold Applications

GHK-modified scaffolds, including alginate hydrogels, 3D-printed silk substrates with polydopamine coatings, and collagen membranes, consistently outperform unmodified counterparts for promoting fibroblast activity, stem cell osteogenic differentiation, vascularization, and trophic factor release. These applications are exploratory but clinically relevant: the bone-tissue engineering literature suggests a viable path for GHK-Cu in surgical reconstruction, where sustained-release scaffolds are the established deliery format.

6.7 Surgical Wound Healing Evidence (Mohs, Laser Resurfacing, Skin Grafts, Post-Radiation Repair)

The surgical wound healing literature for GHK-Cu is the area of greatest divergence between mechanistic plausibility, anecdotal clinical adoption, and the rigor of published evidence. The peptide is widely used in post-procedural cosmetic dermatology; copper tripeptide-containing creams have been part of post-laser, post-Mohs, post-microneedling, and post-hair-transplant care regimens for nearly two decades, but the published RCT base specific to surgical indications is small and methodologically limited. Across the inclusion window, four lines of evidence are relevant: post-laser resurfacing, irradiated tissue and post-radiation surgical sites, Mohs micrographic surgery wounds, and skin graft and donor-site healing. A fifth indication, diabetic ulcer healing, is addressed under chronic wound healing in Section 6.4, but is reframed here insofar as diabetic ulcer surgical debridement and split-thickness graft coverage are explicitly surgical interventions.

6.7.1 CO₂ Laser Resurfacing (Huh and Koch, 2006)

The single registered, randomized, evaluator-blinded trial of GHK-Cu in a surgical-cosmetic context is the Huh and Koch study published in the Archives of Facial Plastic Surgery in 2006 [76]. Thirteen patients undergoing circumoral CO₂ laser resurfacing were randomized post-procedure to receive either a petrolatum-based skin care regimen (Biomedic Gentle Healing Ointment followed by La Roche-Posay moisturizers) or a GHK-Cu-containing equivalent (Complex Cu3 Intensive Tissue Repair Crème followed by Complex Cu3 Post-Laser Lotion and Neova Therapy products). The primary endpoints were objective: computer-quantified erythema, blinded evaluator scoring of wrinkles, and overall skin quality at twelve weeks. Patient satisfaction was a secondary endpoint, measured by a validated questionnaire.

The objective endpoints were null. Computer analysis and blinded evaluators found no statistically significant difference between groups for the rate of resolution of post-procedure erythema, no difference in wrinkle improvement, and no difference in objective skin quality scoring. The patient-reported endpoint, however, showed a different pattern: subjects randomized to the GHK-Cu arm reported significantly higher satisfaction with overall skin quality at twelve weeks (P = 0.04) [76]. The authors’ interpretation was cautious; they noted that GHK-Cu skin care products placed on CO₂ laser-resurfaced skin offered no significant reduction or resolution of post-treatment erythema, no significant improvement in objective measures of wrinkles or overall skin quality but produced a significant patient-satisfaction difference.

This study deserves careful interpretation. With n=13 it is dramatically underpowered to detect anything but very large effects, and its objective endpoints are subject to ceiling effects in an indication where the underlying CO₂ laser is doing the bulk of the resurfacing work. The patient satisfaction divergence is methodologically interesting: it could reflect a genuine subjective benefit, such as perceived improvements in skin feel, a placebo effect amplified by product packaging differences, or a real but small objective benefit that the underpowered objective measures could not detect. The study illustrates the broader pattern in GHK-Cu surgical research characterized by small studies with mixed objective and subjective endpoints, rather than adequately powered trials with consistent outcome measures.

6.7.2 Irradiated Tissue and Post-Radiation Surgical Sites (Pollard et al., 2005)

Pollard et al. (2005), in the same Archives of Facial Plastic Surgery journal, examined GHK-Cu’s effect on irradiated fibroblasts, a model directly relevant to surgical reconstruction in patients with prior head and neck radiation therapy [5]. Wound healing in irradiated tissue is clinically difficult: progressive obliteration of the capillary bed and fibrotic tissue accumulation produce high rates of dehiscence, infection, and poor cosmetic outcome after surgical reconstruction. Pollard’s group cultured normal and irradiated fibroblasts (treated with 50 Gy in 25 fractions) with GHK-Cu and measured cell growth and growth-factor secretion. The peptide stimulated growth-factor expression in irradiated cells and partially restored their proliferative capacity, suggesting a modulatory role for GHK-Cu in the autocrine growth factor milieu of post-radiation tissue.

The clinical inference, that topical or scaffold-delivered GHK-Cu might improve outcomes in surgical reconstruction of previously irradiated tissue, has not been tested in a registered human trial. This is a tractable indication for a future clinical study: head-and-neck cancer survivors undergoing reconstructive surgery represent a defined population with high baseline complication rates, well-validated outcome measures, and clinical equipoise.

6.7.3 Mohs Micrographic Surgery Wounds

Mohs micrographic surgery (MMS) is the standard of care for high-risk non-melanoma skin cancers in cosmetically and functionally sensitive areas, with annual case volumes in the United States exceeding two million procedures. MMS-defect reconstruction encompasses primary closure, local flap repair, full-thickness and split-thickness skin grafts, and second-intention healing. Cosmetic outcomes vary substantially by defect size, anatomic location, repair technique, and individual patient factors. Saleh et al. (2021), in a prospective single-center blinded study of patient-versus-surgeon agreement on MMS cosmetic outcomes, documented systematic divergence between patient and surgeon assessments [77], establishing patient-reported cosmetic outcome as a clinically meaningful and independently measured endpoint.

Despite widespread off-label use of GHK-Cu creams in post-Mohs care, no registered RCT of GHK-Cu specifically for Mohs wound healing has been published within the inclusion window. The Pickart 2008 review article (cited via record 32 of the master table) and the Pollard 2005 paper [5] both reference unpublished or proprietary clinical work as evidence for GHK-Cu’s wound-healing efficacy in Mohs surgical wounds, but the underlying trial data remain unavailable in the peer-reviewed primary literature within the inclusion window. This is a notable gap. A registered, blinded RCT of GHK-Cu (topical, microneedle-adjacent, or scaffold-incorporated) versus standard post-Mohs care, with patient-reported outcomes and blinded photographic assessment as co-primary endpoints, would substantially advance the field.

6.7.4 Skin Grafts, Donor Sites, and Hair Transplant Wounds

GHK-Cu is incorporated into proprietary post-procedural products marketed for split-thickness skin graft donor sites, full-thickness graft recipient beds, and hair-transplant follicular unit extraction (FUE) and follicular unit transplantation (FUT) recipient and donor sites. The aesthetic medicine review literature documents broad off-label adoption of GHK-Cu in these contexts [78], and the foundational Pickart patent literature describes copper tripeptide compositions specifically for wound healing in mammals, including post-graft healing [61]. Peer-reviewed RCT evidence specific to these surgical indications remains sparse within the inclusion window. The Khanna 2025 dermaroller plus copper peptide trial for acne scars [17] is the most methodologically rigorous demonstration of GHK-Cu combined with a microneedle-based delivery vehicle producing additive benefit over the device alone, and the underlying mechanism, controlled microinjury followed by GHK-Cu-supported repair, is mechanistically transferable to surgical settings.

The recent Kuceki 2025 study of microneedle tattooing of a minoxidil-dutasteride-copper peptide combination for androgenetic alopecia [18] establishes feasibility of multi-active microneedle delivery in an aesthetic surgery-adjacent indication, although the study design (n = 1 case report with AI-assisted blinded evaluation) is insufficient to establish efficacy.

6.7.5 Synthesis and Evidence Gaps

Across the surgical wound healing literature for GHK-Cu, three patterns are evident.

First, the mechanistic case is well supported. GHK-Cu’s dual role as a copper-delivery vehicle for lysyl oxidase activity and as a TGF-β3-modulating, anti-inflammatory, antioxidant matricryptin maps directly onto the pathophysiology of surgical wound healing, particularly in compromised contexts such as irradiated tissue, diabetes, smoking, advanced age, where the endogenous repair signaling is impaired. The mechanism is not speculative; it is established by six decades of bench biology.

Second, the published clinical evidence specific to surgical wound healing is more limited than the off-label adoption suggests. The Huh 2006 trial [76] is the only registered RCT in the inclusion window, and it is small and with mixed results. The Pollard 2005 fibroblast study [5] establishes biological plausibility for post-radiation indications without testing them clinically. Off-label use in Mohs, skin grafts, and hair-transplant settings is widespread but unsupported by registered RCT data within the inclusion window.

Third, the delivery question remains the key bottleneck. Topical GHK-Cu cream applied to intact skin around a surgical wound has limited stratum corneum penetration, and once applied directly to the wound bed, the peptide is rapidly degraded by carboxypeptidase activity in the wound environment. Microneedle-mediated delivery into peri-incisional tissue, scaffold-incorporated GHK-Cu in graft beds, and stabilized self-assembling peptide formulations resistant to proteolysis [12, 22, 79] represent the three delivery strategies with the strongest preclinical supporting evidence for surgical wound healing applications. However, all three delivery strategies remain untested in a registered RCT for surgical indications within the inclusion window. Closing this gap is the central translational opportunity for GHK-Cu in modern surgical care.

7. Comparator Analysis (Stratified by Study Model)

The comparator analysis tables below follow the methodological constraint that GHK-Cu studies should be compared to alternative therapies tested in equivalent models. An in vitro fibroblast study is compared to other in vitro fibroblast studies; a rodent wound model is compared to other rodent wound models; a human topical RCT is compared to other human topical RCTs.

7.1 In Vitro Fibroblast / Keratinocyte Comparator (Table 2)

In Table 2 the collagen and elastin induction profile of GHK-Cu is comparable to or, when paired with hyaluronic acid, has been reported to exceed the collagen IV induction of standard cosmetic peptides like Matrixyl. Its mechanistic profile is broader: instead of acting through one receptor pathway, GHK-Cu has been associated with broad transcriptional effects. In fibroblast head-to-head tests, GHK-Cu and tretinoin produce overlapping but mechanistically different procollagen induction, which makes them potentially complementary rather than directly competitive.

7.2 In Vivo Rodent Wound Healing Comparator (Table 3).

In Table 3 in rodent wound models, GHK-Cu’s most pronounced effects come from delivery-engineered formulations (PIC, liposomes, AgNP). Free GHK-Cu produces a weaker signal in these same models. The growth-factor comparators (EGF, FGF) produce comparable wound-closure acceleration in similar mouse and rat models. The mechanism is different; direct mitogenic activity versus broader transcriptional modulation; but the magnitudes overlap. The implication for clinical development is that GHK-Cu may not need to outperform EGF or FGF on raw closure rate to be a useful therapy; its broader anti-inflammatory and antioxidant profile could offer advantages in chronic wounds where inflammation is a persistent driver.

7.4 Microneedle-Based Delivery Comparator (Table 5).

In Table 5, when microneedling is paired with topical actives, the clinical literature for vitamin C, ferulic acid, tranexamic acid, and PRP demonstrates generally additive or synergistic effects. . The same pairing for GHK-Cu has only been tested in small dermaroller and tattooing studies. There is no published human trial of GHK-Cu delivered via dissolvable, hollow, or solid microneedle arrays, the formats with the strongest pharmacokinetic evidence from Li 2015. This remains a major evidence gap in the current literature.

8. Critical Appraisal and Limitations of the Existing Literature

Across the 64 included records, several methodological limitations recur and warrant consideration when interpreting the evidence.

Sample size and power. Most human studies of GHK-Cu have fewer than 100 participants and run between 8 and 16 weeks. Several frequently cited “trials” (Leyden 2002 facial cream; Leyden 2002 eye cream; Abdulghani 1999) were published only as conference abstracts and have not appeared in full peer-reviewed form. This is the principal vulnerability of the human evidence base.

Authorship and conflict of interest. Approximately 35% of the GHK-Cu primary literature in the inclusion window includes Loren Pickart or Anna Margolina (Skin Biology Inc.) as an author. Pickart was the original isolator of the peptide and held commercial interests in the field for decades. The contributions of this group are scientifically substantive, and the gene-expression work is foundational. However, the concentration of authorship in a small number of investigators limits the independence of the evidence base.

Study model heterogeneity. GHK-Cu has been tested in vitro at concentrations ranging from 10⁻¹² to 10⁻⁵ M; topically at 0.05% to 2%; intraperitoneally at 0.2 to 20 µg/g/day; and in liposomes, ionic liquids, microemulsions, hydrogels, alginate scaffolds, and silver nanoparticles. The biphasic dose-response means that “GHK-Cu treatment” does not represent a single intervention. Without standardized comparators across laboratories, dose-finding for a clinical microneedle protocol cannot be answered from the existing literature and must be addressed by a dedicated phase I/II clinical study.

Outcome measure heterogeneity. Wrinkle assessment ranges from optical profilometry to expert grading to subjective participant report. Wound healing is variously measured by closure rate, collagen content, GSH, granulation tissue thickness, and histology. Hair growth is assessed by trichoscopy, AI image analysis, follicle elongation in organ culture, and area regrowth. This heterogeneity of outcome measures across domains therefore renders quantitative pooling infeasible.

Risk of bias by domain. Of the human studies within the inclusion window, randomization procedures are rarely described in detail, allocation concealment is frequently unreported, and blinding of outcome assessors is inconsistent. The Khanna 2025 dermaroller-versus-dermaroller-plus-GHK-Cu acne scar study is among the better-reported RCTs in the human peptide literature and offers a useful template for future trial reporting [17].

Translation gap. The most consequential limitation is the disconnect between the depth of the preclinical evidence and the shallowness of the clinical evidence. No peer-reviewed phase III RCT of GHK-Cu in any human indication. Additionally, no peer-reviewed phase II RCT pairing GHK-Cu with microneedle delivery has been published in any human indication.

Figure 4: Translational roadmap for GHK-Cu: from mechanistic evidence to phase II human microneedle trials.

As detailed in Figure 4, a five-stage evidence ladder synthesizing the maturity gradient identified across the 64 included studies. Stages 1-3 represent domains in which the evidence base is strong and mature (deep to lighter teal). Stage 1 (mechanistic evidence) encompasses collagen, decorin, and glycosaminoglycan synthesis; lysyl oxidase activity with copper as catalytic cofactor; NF-κB modulation and Nrf2/antioxidant defense; p63 and integrin signaling in basal keratinocytes; and matricryptin biology with TGF-β₃ pathway crosstalk. Stage 2 (preclinical efficacy) covers fibroblast and keratinocyte culture assays, acute and chronic wound-healing rodent models, hair-growth and dermal-papilla models, pulmonary and intestinal anti-inflammatory models, and ex vivo human skin diffusion and explant studies. Stage 3 (delivery-system evidence) summarizes the expanding portfolio of microneedle arrays, liposomes and lipid nanoparticles, ionic-liquid microemulsions, hydrogels, electrospun scaffolds, and early-stage iontophoresis and sonophoresis platforms. Stage 4 (amber) characterizes the current human evidence as limited, heterogeneous, and underpowered: small topical cosmetic studies, small device-assisted acne-scar and alopecia trials, predominantly open-label or weakly-controlled designs, and substantial inter-study variability in formulation, dose, and endpoint selection. Stage 5 (coral) represents the actionable gap and the operative recommendation of this review: adequately powered phase II randomized controlled trials in photoaging, atrophic acne scarring, androgenetic alopecia, and diabetic/chronic wounds, paired with a head-to-head human pharmacokinetic study comparing free topical, liposomal, and microneedle-assisted GHK-Cu delivery. Visual emphasis on Stage 5, marked by a thicker border and italic capstone, reflects the central argument of this review: the field no longer needs to establish that GHK-Cu is biologically active, but rather to determine which delivery platform, dose, and indication produce meaningful human benefit. Abbreviations: GAG, glycosaminoglycan; LOX, lysyl oxidase; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; Nrf2, nuclear factor erythroid 2-related factor 2; TGF-β₃, transforming growth factor beta 3; PK, pharmacokinetic; RCT, randomized controlled trial.

9. Discussion: The Case for Human Topical-Microneedle GHK-Cu Trials

The synthesis above provides a clear answer to the question of where the GHK-Cu field most urgently needs investment.

The pharmacological foundation is well characterized. GHK-Cu acts at low nanomolar concentrations on a defined and reproducible set of cellular targets (NF-κB suppression, Nrf2 activation, MMP/TIMP rebalancing, collagen and elastin synthesis induction, p63 stemness preservation, dermal papilla cell proliferation). The connectivity-map evidence shows that this is not a single-pathway agent but a transcriptional remodeler [1]. The animal evidence in cutaneous wound healing, hair growth, and inflammation is extensive and consistent.

The translational bottleneck is delivery. GHK-Cu does not cross intact stratum corneum at therapeutic doses [19]. Microneedle pretreatment overcomes this barrier in human cadaver skin to a degree that is dramatic and reproducible: from essentially zero to 134 ± 12 nanomoles peptide and 705 ± 84 nanomoles copper in nine hours [2]. Liposomes, ionic-liquid microemulsions, and silver nanoparticle conjugates produce additional permeation enhancements that compound with the microneedle effect.

The clinical literature has not caught up. The Khanna 2025 dermaroller study is the closest published evidence to a human microneedle-mediated GHK-Cu trial, and it used a 1.5 mm dermaroller, a relatively crude device, with a 0.5-1% serum [17]. The Kuceki 2025 case series used a tattooing device for the combined delivery of three actives [18]. Neither isolates GHK-Cu, neither tests dissolvable or hollow microneedle arrays of the kind that produced the Li 2015 permeation data, and neither was sized to detect a clinically meaningful effect at conventional alpha and power thresholds.

Four indications are most ready for human microneedle-mediated GHK-Cu trials:

1. Photoaging. A double-blind, placebo-controlled, split-face RCT comparing a dissolvable microneedle patch with GHK-Cu against a dissolvable microneedle patch with vehicle, in approximately 120 women aged 45-65 with moderate photodamage, over 12-24 weeks, with optical profilometry, cutometry, and high-frequency ultrasound endpoints. Comparator arms could include topical tretinoin 0.025% as a positive control and topical pal-KTTKS as a peptide control.
2. Atrophic acne scarring. An RCT comparing solid microneedle (1.5 mm) device monotherapy against the same device followed by GHK-Cu serum, in 80-120 patients, with Goodman & Baron scoring at baseline and weeks 4, 12, and 24, plus blinded photographic assessment. A third arm incorporating a vitamin C serum would allow head-to-head comparison.
3. Androgenetic alopecia. A four-arm RCT comparing daily topical 5% minoxidil; daily topical 5% minoxidil plus monthly microneedle GHK-Cu serum; monthly microneedle GHK-Cu serum alone; and microneedle vehicle alone. Primary endpoints would include: trichoscopy hair count, hair shaft diameter, AI image analysis at 3, 6, and 12 months. The Liu 2023 finding that GHK-Cu in IL-microemulsion outperformed minoxidil in mice [12] is the most substantial preclinical justification for testing this hierarchy in humans.
4. Diabetic foot ulcer / chronic wound. An RCT comparing standard wound care alone, standard wound care plus GHK-Cu hydrogel dressing, and standard wound care plus GHK-Cu via microneedle patch, in patients with grade 1 or 2 University of Texas wound classification, with closure rate, time-to-50%-closure, and the Bates-Jensen Wound Assessment Tool as primary endpoints.

In each of these four indications, the clinical development infrastructure required is conventional, the safety signal from existing GHK-Cu use is strongly favorable, and the comparator regimen is well-established. The path forward is clear and what the field lacks is not mechanistic understanding but investment and trial execution.

10. Conclusions and Recommendations for Future Research

GHK-Cu is among the most extensively characterized regenerative tripeptides in the published biomedical literature. After fifty years of research, its mechanism is mapped at the cellular, transcriptional, and animal-physiology level with remarkable depth. The remaining question for the field is no longer whether GHK-Cu is biologically active, as the evidence clearly demonstrates it is, but rather which delivery platform, in which indication, at which dose, produces a clinically meaningful and measurable effect in humans.

The microneedle delivery question is the single most consequential. Microneedle technology has reached the point at which dissolvable, hollow, and solid-coated arrays can be manufactured at scale, regulatory pathways are being established for the device-active combinations, and the pharmacokinetic basis for GHK-Cu delivery via this route is supported by Li 2015 and replicated across the ionic-liquid, liposome, and microemulsion literature.

Specific recommendations for next-step research:

1. A registered phase II RCT of microneedle-delivered GHK-Cu for moderate photoaging, with cutometry, optical profilometry, and biopsy histology as endpoints, designed against tretinoin and Matrixyl as active comparators.
2. A registered phase II RCT of microneedle-delivered GHK-Cu for atrophic acne scarring, designed against microneedling alone as the active comparator, with Goodman & Baron scoring and blinded photographic evaluation.
3. A registered phase II RCT of microneedle-delivered GHK-Cu for androgenetic alopecia, designed against topical minoxidil 5% as the active comparator and stratified by sex.
4. A registered phase II RCT of microneedle-patch GHK-Cu for chronic diabetic wound healing, designed against EGF hydrogel as the active comparator.
5. A standardized GHK-Cu pharmacokinetic study in healthy human volunteers, with serial plasma sampling after microneedle, free topical, and liposomal application, to define the dose-response relationship and inform protocol design across indications.
6. A registered systematic review of GHK-Cu protocols with PROSPERO registration, to formalize the methods applied here at the level required for a Cochrane-comparable evidence synthesis.

The peptide is not lacking in mechanism, dose-response data, or animal validation. What it lacks are the human trials that would translate fifty years of bench science into patient-facing therapy. Closing that gap is the critical path work the field now requires.

Authors’ Contribution:

N.N. and H.M. conceptualized the project; N.N., H.M., K.G.V., and K.B.V. performed literature search and selected articles; N.N., H.M., K.G.V., and K.B.V. data collection and analysis; N.N., H.M., K.G.V., and K.B.V.  wrote the initial draft of the manuscript and prepared all figures and tables; D.K.A. critically reviewed and edited the manuscript; D.K.A. provided research funds and resources. All authors reviewed and approved the manuscript for submission to the American Journal of Clinical Dermatology.

Funding:

The research work of DKA is supported by the R25AI179582 grant from the National Institutes of Health, USA. The contents of this research article are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.

Data Availability:

No new pre-clinical or clinical studies were performed, and all findings were gathered from the published articles and critically reviewed. All collected findings and their analyses are deposited in the Cloud provided by WesternU and are also available with the corresponding author upon request through the proper channel.

Competing interests:

All authors have read the manuscript and declare no conflict of interest. No writing assistance was utilized in the production of this manuscript.

Consent for publication:

All authors have read the manuscript and consented for publication.

References

1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 19 (2018): 1987.
2. Li H, Low YSJ, Chong HP, et al. Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharm Res. 32 (2015): 2678-2689.
3. Kang YA, Choi HR, Na JI, et al. Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Arch Dermatol Res. 301 (2009): 301-306.
4. Choi HR, Kang YA, Ryoo SJ, et al. Stem cell recovering effect of copper-free GHK in skin. J Pept Sci. 18 (2012): 685-690.
5. Pollard JD, Quan S, Kang T, Koch RJ. Effects of Copper Tripeptide on the Growth and Expression of Growth Factors by Normal and Irradiated Fibroblasts. Arch Facial Plast Surg. 7 (2005): 27-31.
6. Badenhorst T, Svirskis D, Merrilees M, et al. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters. J Aging Sci. 4 (2016): 1000166.
7. Jiang F, Wu Y, Liu Z, et al. Synergy of GHK-Cu and hyaluronic acid on collagen IV upregulation via fibroblast and ex-vivo skin tests. J Cosmet Dermatol. 22 (2023): 2598-2604.
8. Arul V, Gopinath D, Gomathi K, Jayakumar R. A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices. Life Sci. 80 (2007): 275-284.
9. Wang X, Liu B, Xu Q, et al. GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair Regen. 25 (2017): 270-278.
10. Islam R, Bilal H, Wang X, Zhang L. Tripeptides Ghk and GhkCu-modified silver nanoparticles for enhanced antibacterial and wound healing activities. Colloids Surf B Biointerfaces. 236 (2024): 113785.
11. Tian L-W, Luo D, Chen D, et al. Co-delivery of bioactive peptides by nanoliposomes for promotion of hair growth. J Drug Deliv Sci Technol. 72 (2022): 103381.
12. Liu T, Liu Y, Zhao X, et al. Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide application. Bioact Mater. 32 (2024): 502-513.
13. Park JR, Lee H, Kim SI, Yang SR. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget. 7 (2016): 58405-58417.
14. Zhang Q, Yan L, Lu J, Zhou X. Glycyl-L-histidyl-L-lysine-Cu²⁺ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Front Mol Biosci. 9 (2022): 925700.
15. Mao S, Huang J, Li J, et al. Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms. Front Pharmacol. 16 (2025): 1551843.
16. Ho LK, Yan CH, Lai EW, et al. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res. 33 (2015): 1147-1156.
17. Khanna NA et al. A study comparing the effect of dermaroller versus dermaroller with copper peptide in the management of acne scars. J Cutan Aesthet Surg. (2025).
18. Kuceki G, Coppinger C, Ragi SD, et al. Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia assessed by artificial intelligence and blinded evaluators. JAAD Int. 19 (2025): 67-69.
19. Hostynek JJ, Dreher F, Maibach HI. Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy. Inflamm Res. 59 (2010): 983-988.
20. Dymek M, Olechowska K, Hąc-Wydro K, Sikora E. Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application. Pharmaceutics. 15 (2023): 2485.
21. Liu T, Wang J, Wang W, et al. Noninvasive and Efficient Peptide Delivery by a Novel Biocompatible Ionic Liquid. ACS Sustain Chem Eng. 10 (2022): 11919-11928.
22. Sharma S, Anwar MF, Dinda AK, et al. Polyaspartic acid, 2-acrylamido-2-methyl propane sulfonic acid and sodium alginate based biocompatible stimuli responsive polymer gel for controlled release of GHK-Cu peptide for wound healing. J Biomater Appl. 36 (2022): 1832-1844.
23. Klontzas ME, Reakasame S, Silva R, et al. Oxidized alginate hydrogels with the GHK peptide enhance cord blood mesenchymal stem cell osteogenesis: A paradigm for metabolomics-based evaluation of biomaterial design. Acta Biomater. 88 (2019): 224-240.
24. Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 30 (2007): 834-839.
25. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 19 (2008): 969-988.
26. Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev. (2012): 324832.
27. Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: Resetting the Human Genome to Health. Biomed Res Int. (2014): 151479.
28. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. (2015): 648108.
29. Pickart L, Vasquez-Soltero JM, Margolina A. GHK-Cu may Prevent Oxidative Stress in Skin by Regulating Copper and Modifying Expression of Numerous Antioxidant Genes. Cosmetics. 2 (2015): 236-247.
30. Pickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sci. 7 (2017): 20.
31. Pickart L, Margolina A. The Effect of the Human Plasma Molecule GHK-Cu on Stem Cell Actions and Expression of Relevant Genes. OBM Geriatr. 2 (2018): 009.
32. Pickart L, Vasquez-Soltero JM, Margolina A. Skin Regenerative and Anti-Cancer Actions of Copper Peptides. Cosmetics. 5 (2018): 29.
33. Pickart L, Margolina A. Modulation of Gene Expression in Human Breast Cancer MCF7 and Prostate Cancer PC3 Cells by the Human Copper-Binding Peptide GHK-Cu. OBM Genet. 5 (2021): 128.
34. Pickart L, Vasquez-Soltero JM, Pickart FD, Majnarich J. GHK, the Human Skin Remodeling Peptide, Induces Anti-Cancer Expression of Numerous Caspase, Growth Regulatory, and DNA Repair Genes. J Anal Oncol. 3 (2014): 79-89.
35. Jose S, Hughbanks ML, Binder BYK, et al. Enhanced trophic factor secretion by mesenchymal stem/stromal cells with Glycine-Histidine-Lysine (GHK)-modified alginate hydrogels. Acta Biomater. 2014; 10 (5): 1955-1964.
36. Gul NY, Topal A, Cangul IT, Yanik K. The effects of topical tripeptide copper complex and helium-neon laser on wound healing in rabbits. Vet Dermatol. 19 (2008): 7-14.
37. Tenaud I, Sainte-Marie I, Jumbou O, Litoux P, Dréno B. In vitro modulation of keratinocyte wound healing integrins by zinc, copper and manganese. Br J Dermatol. 140 (1999): 26-34 (cited via Pickart 2018; included for keratinocyte integrin context).
38. Ogórek K, Nowak K, Wadych E, et al. Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? Molecules. 30 (2025): 136.
39. Resnik J et al. Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review. Int J Med Sci. 22 (2025): 4175-4193.
40. Kang C, Lu D. Combined Effect of Microneedling and Platelet-Rich Plasma for the Treatment of Acne Scars: A Meta-Analysis. Front Med. 8 (2022): 788754.
41. Patel R et al. Microneedling in Dermatology: A Comprehensive Review of Applications, Techniques, and Outcomes. Cureus. 16 (2024): e71286.
42. Singh D et al. Microneedling for Non-cosmetic Dermatologic Conditions: A Systematic Review of Efficacy and Safety. Cureus. 2025.
43. Chilicka K, Rusztowicz M, Szyguła R, et al. Ascorbic Acid Treatments as Effective and Safe Anti-Aging Therapies for Sensitive Skin. Antioxidants. 13 (2024): 174.
44. Zasada M, Markiewicz A, Drożdż Z, et al, Budzisz E. Preliminary randomized controlled trial of antiaging effects of l-ascorbic acid applied in combination with no-needle and microneedle mesotherapy. J Cosmet Dermatol. 18 (2019): 843-849.
45. Krzywda M et al. Effects of CE Ferulic Combined with Microneedling in the Treatment of Pigmentary Disorders: A Monocentric, Split Face, Comparative Study. Cosmetics. 11 (2024): 101.
46. Robinson LR, Fitzgerald NC, Doughty DG, et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 27 (2005): 155-160.
47. Kang S, Bergfeld W, Gottlieb AB, et al. Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin: a two-year, randomized, placebo-controlled trial. Am J Clin Dermatol. 6 (2005): 245-253.
48. Pessanha FS, de Oliveira BGRB, Oliveira BC, et al. Effectiveness of Epidermal Growth Factor Loaded Carboxymethylcellulose (EGF-CMC) Hydrogel in Biofilm Formation in Wounds of Diabetic Patients: A Randomized Clinical Trial. Gels. 9 (2023): 117.
49. Wei Y, Li J, Huang Y, et al. The clinical effectiveness and safety of using epidermal growth factor, fibroblast growth factor and granulocyte-macrophage colony stimulating factor as therapeutics in acute skin wound healing: a systematic review and meta-analysis. Burns Trauma. 10 (2022): tkac002.
50. de Oliveira CM et al. The use of epidermal growth factor in dermatological practice. Int J Dermatol. (2024).
51. Sun S et al. Advances in Transdermal Delivery Systems for Treating Androgenetic Alopecia. Pharmaceutics. 17 (2025): 984.
52. Tahoun AI et al. A study comparing the effect of microneedling with tranexamic acid versus microneedling with vitamin C in the treatment of melasma. Dermatol Ther. (2022).
53. Brown GL, Nanney LB, Griffen J, et al. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med. 321 (1989): 76-79 (cited via Wei 2022 within window).
54. Sadgrove NJ. Topical and nutricosmetic products for healthy hair and dermal antiaging using “dual-acting” (2 for 1) plant-based peptides, hormones, and cannabinoids. FASEB BioAdvances. 3 (2021): 601-620.
55. Madaan A, Verma R, Singh AT, Jaggi M. Review of Hair Follicle Dermal Papilla cells as in vitro screening model for hair growth. Int J Cosmet Sci. 40 (2018): 429-450.
56. Bossak-Ahmad K, Frączyk T, Bal W, Drew SC. The Sub-picomolar Cu²⁺ Dissociation Constant of Human Peptide Hepcidin-25. Molecules. 24 (2019): 3460 (coordination chemistry context for GHK-Cu).
57. Apone F, Barbulova A, Colucci MG. Plant and microalgae derived peptides are advantageously employed as bioactive compounds in cosmetics. Front Plant Sci. 10 (2019): 756.
58. Errante F, Ledwoń P, Latajka R, et al. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 8 (2020): 572923.
59. Pickart L. Skin Regenerative and Anti-Cancer Actions of Copper Peptides. Cosmetics. 5 (2018): 29. (separately listed under record 32 of master table; shown here for reference completeness)
60. Yamamoto K, Lee LK et al. The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. 3 (2021): 28-32.
61. Pickart L. Compositions for accelerating wound healing in mammals containing cupric salt or complexes with amino acids or peptides (US Patent 4760051, 1988; cited only as historical reference via Pickart 2008).
62. Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. FEBS Lett. 238 (1988): 343-346 (foundational; cited only via post-2005 review articles).
63. Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺ in rat experimental wounds. J Clin Invest. 92 (1993): 2368-2376 (foundational; cited only via post-2005 reviews).
64. Mulder GD, Patt LM, Sanders L, Rosenstock J, Altman MI, Hanley ME, Duncan GW. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair Regen. 1994; 2 (1994): 259-269 (foundational human trial; cited only via post-2005 reviews).
65. Lee HG, Yoo HG, Pyo HK, et al. The additive effects of minoxidil and retinol on human hair growth in vitro. Biol Pharm Bull. 2007;30(1): 21-26.
66. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. (2015): 648108 (full-text reference for record 12 of master table; provided again for reader convenience).
67. Mhanna R, Nordström S, Frassetto LA, et al. Nanoengineered Self-Assembling Peptides with Increased Proteolytic Stability Promote Wound Healing. ACS Appl Mater Interfaces. 2025; advance online publication (three-phase wound healing model and proteolytic stability of GHK-based assemblies).
68. Ricard-Blum S, Salza R. Matricryptins and matrikines: biologically active fragments of the extracellular matrix. Exp Dermatol. 2014;23(7):457-463 (matricryptin/matrikine framework, GHK as endogenous matricryptin).
69. Lane TF, Iruela-Arispe ML, Johnson RS, Sage EH. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol. 125 (1994): 929-943 (SPARC as parent protein of (K)GHK; angiogenic peptide release; cited only via post-2005 reviews per Section 4.2).
70. Lindsey ML, Iyer RP, Zamilpa R, et al. A Novel Collagen Matricryptin Reduces Left Ventricular Dilation Post-Myocardial Infarction by Promoting Scar Formation and Angiogenesis. J Am Coll Cardiol. 66 (2015): 1364-1374 (collagen Iα2 source of GHK; matricryptin biology framework).
71. Rucker RB, Kosonen T, Clegg MS, et al. Copper, lysyl oxidase, and extracellular matrix protein cross-linking. Am J Clin Nutr. 67 (1998): 996S-1002S (copper as essential cofactor for lysyl oxidase and ECM cross-linking; cited only via post-2005 reviews per Section 4.2).
72. Martínez-Revelles S, García-Redondo AB, Avendaño MS, et al. Lysyl Oxidase Induces Vascular Oxidative Stress and Contributes to Arterial Stiffness and Abnormal Elastin Structure in Hypertension: Role of p38MAPK. Antioxid Redox Signal. 27 (2017): 379-397 (LOX family overview; LOX, LOXL1-4 copper dependence).
73. Beretta G, Artali R, Regazzoni L, et al. Glycyl-histidyl-lysine (GHK) is a quencher of α,β-4-hydroxy-trans-2-nonenal: a comparison with carnosine. Insights into the mechanism of reaction by electrospray ionization mass spectrometry, ¹H NMR, and computational techniques. Chem Res Toxicol. 20 (2007): 1309-1314.
74. Beretta G, Aldini G, Facino RM, et al. Acrolein sequestering ability of the endogenous tripeptide glycyl-histidyl-lysine (GHK): characterization of conjugation products by ESI-MSn and theoretical calculations. J Pharm Biomed Anal. 47 (2008): 596-602.
75. Miller DM, DeSilva D, Pickart L, Aust SD. Effects of glycyl-histidyl-lysyl chelated Cu(II) on ferritin dependent lipid peroxidation. Adv Exp Med Biol. 264 (1990): 79-84 (foundational ferritin-iron-lipid peroxidation mechanism; cited only via post-2005 reviews per Section 4.2).
76. Huh CH, Seo KI, Kim SD, et al. Effects of Topical Copper Tripeptide Complex on CO₂ Laser-Resurfaced Skin. Arch Facial Plast Surg. 2006;8(4):252-256 (n=13 RCT; objective endpoints null, patient-satisfaction endpoint significant).
77. Saleh K, Ingvar Å, Kappelin J, et al. Agreement between patients and surgeons on assessments of the cosmetic outcomes of Mohs micrographic surgery: Results of a single-center blinded prospective study. JAAD Int. 5 (2021): 38-40 (patient-reported cosmetic outcome divergence from surgeon assessment; methodological framework for Mohs cosmetic endpoints).
78. Anti Age Magazine editorial board. Copper Tripeptide-1 Growth Factor in Aesthetic Medicine. Anti Age Magazine. 2017 (industry/clinical reference documenting off-label use of copper tripeptide-1 in laser wounds, surgical wounds, burns, non-healing ulcers, Mohs, hair transplants, and skin grafts; cited only as practitioner-pattern reference, not as primary efficacy evidence).
79. Arul V, Masilamoni JG, Jesudason EP, et al. Glycyl histidyl lysine-Cu²⁺, a human plasma tripeptide accelerates wound healing of cutaneous wounds in normal as well as in diabetic rat models. J Drug Target. 20 (2012): 223-229.